Treating Hives / Urticaria

Expert Evaluation and Evidence-Based Management

Raised, intensely itchy welts that appear suddenly across your skin and disappear just as quickly, only to return hours later somewhere else. A rash that moves, shifts, and spreads without a clear explanation. Hives that have been erupting daily for weeks or months with no obvious trigger. Urticaria is one of the most common and most disruptive skin conditions evaluated in dermatology, and for many patients, it becomes a source of significant daily anxiety and uncertainty.

Urticaria, commonly called hives, affects approximately 20 percent of people at some point during their lifetime. In its acute form, it resolves within days to weeks. In its chronic form, defined as hives occurring on most days for six weeks or longer, it can persist for years and profoundly affect sleep, work, and quality of life. Chronic urticaria affects roughly 1 percent of the global population at any given time and is significantly underdiagnosed and undertreated because it is often mistaken for allergic reactions, other skin conditions, or dismissed as a condition that simply cannot be controlled.

At Connolly Dermatology, we provide expert evaluation and urticaria treatment guided by evidence-based care. Our board-certified dermatologists identify the type and underlying mechanism of your hives, conduct targeted diagnostic workups when indicated, distinguish urticaria from the conditions that closely mimic it, and design management plans that move systematically through evidence-supported therapies to achieve real, sustained control. From second-generation antihistamines through the biologic therapy omalizumab for antihistamine-refractory chronic urticaria, we match every intervention to your specific presentation.

If hives are disrupting your daily life or you cannot identify what is causing them, scheduling an evaluation with a dermatologist provides clarity. Have your skin assessed by the specialists at Connolly Dermatology and get the answers you need to move forward confidently.

Understanding Urticaria

How the Different Types Differ and Why That Distinction Shapes Treatment

Urticaria is not a single, uniform condition. It encompasses several distinct clinical subtypes that differ in their duration, triggers, underlying mechanisms, and required management strategies. The most fundamental classification divides urticaria by duration into acute and chronic forms, and further divides chronic urticaria into spontaneous and inducible subtypes. Identifying the correct type is the essential first step because treatment approaches, diagnostic workups, and prognosis differ significantly across subtypes.

At the cellular level, all forms of urticaria share a common final pathway: mast cell activation. Mast cells, which reside in the skin and mucous membranes, release histamine and other mediators including prostaglandins, leukotrienes, and cytokines when activated. Histamine acts on H1 receptors in superficial dermal blood vessels, causing vasodilation and increased vascular permeability that produces the characteristic edematous wheal. The surrounding flare, or erythema, results from an axon reflex. The itch, which can be severe enough to disrupt sleep and daily function, is driven by histamine’s direct activation of C-fiber sensory nerve endings. The entire process can occur within minutes of a triggering event and resolve equally quickly, which is why individual wheals classically resolve within 24 hours even as new ones continue to form.

Acute Spontaneous Urticaria

Acute urticaria is defined as hives lasting fewer than six weeks. It is the most common form and is frequently self-limiting, resolving completely once the triggering cause is identified and removed or the natural course of the reaction concludes. In children, acute urticaria is most commonly triggered by viral infections, which activate mast cells through non-IgE pathways and produce widespread urticaria that resolves as the infection clears. In adults, acute urticaria may be triggered by food allergens, medications, insect stings, or infections. In many cases, a specific trigger is never definitively identified. Despite its typically benign and self-resolving course, acute urticaria can occasionally be the first manifestation of a more serious allergic reaction including anaphylaxis, which requires prompt recognition and management.

Chronic Spontaneous Urticaria

Chronic spontaneous urticaria is defined as hives occurring on most days for six weeks or longer without a specific identifiable physical trigger. It is the most clinically significant and most difficult to manage form of urticaria. Approximately 45 percent of chronic spontaneous urticaria cases have an autoimmune basis, divided into two immunological subtypes. Type I autoimmunity involves IgE antibodies directed against autoantigens including thyroid peroxidase and double-stranded DNA, producing ongoing mast cell activation through the standard IgE-FcεRI pathway. Type IIb autoimmunity involves IgG autoantibodies directed against either the high-affinity IgE receptor FcεRI on mast cells or against IgE itself, directly activating mast cell degranulation through complement pathways. The remaining cases are classified as idiopathic, though ongoing research continues to identify additional mechanistic pathways. Despite uncertainty about the cause in individual patients, chronic spontaneous urticaria remains highly treatable with appropriate therapy.

Chronic Inducible Urticaria

Chronic inducible urticaria encompasses a group of subtypes in which hives are reproducibly triggered by a specific physical stimulus. Unlike chronic spontaneous urticaria, the causative trigger is known and reproducible. The inducible subtypes include:

•         Symptomatic dermographism: The most common inducible subtype. Firm stroking or pressure on the skin produces a linear wheal along the stroke line within minutes. It is often called “skin writing.” It can occur spontaneously or coexist with chronic spontaneous urticaria.
•         Cold contact urticaria: Hives triggered by contact with cold objects, cold air, or cold water. Can produce anaphylaxis with full body cold water immersion, as in swimming in cold water.
•         Cholinergic urticaria: Small, intensely itchy wheals triggered by elevated core body temperature from exercise, hot baths, emotional stress, or fever. Very common in young adults and often significantly exercise-limiting.
•         Solar urticaria: Hives triggered by UV light exposure, developing within minutes on sun-exposed skin and resolving within hours of sun avoidance.
•         Delayed pressure urticaria: Deep, painful swellings that develop 4 to 6 hours after sustained pressure, such as from a waistband, handbag strap, or prolonged sitting.
•         Aquagenic urticaria: A rare form in which water contact of any temperature produces small wheals and intense itch, independent of the water temperature.
•         Vibration urticaria: Hives triggered by vibratory stimuli, such as from tools, appliances, or jogging on hard surfaces.

Angioedema

Angioedema is the deeper counterpart of urticaria. Where urticaria produces superficial wheals in the dermis, angioedema produces swelling in the deeper dermis, subcutaneous tissue, and submucosal layers. It presents as non-pitting swelling, most commonly involving the lips, eyelids, tongue, genitalia, and extremities. It can affect the gastrointestinal tract, producing cramping and pain, and critically, it can involve the larynx and upper airway, producing a medical emergency. Approximately 40 percent of patients with chronic spontaneous urticaria have episodes of angioedema. It is crucial to distinguish histaminergic angioedema, which occurs alongside urticaria and responds to antihistamines and epinephrine, from bradykinin-mediated angioedema, as occurs in hereditary angioedema from C1 inhibitor deficiency, which does not respond to antihistamines and requires entirely different emergency management.

Urticaria vs. Conditions That Mimic It

Several important skin and systemic conditions produce hive-like lesions that closely resemble urticaria but require entirely different evaluation and treatment. Recognizing these mimics is one of the most clinically important tasks in urticaria management.

These patterns describe typical presentations. Individual cases vary. Any hive-like rash that persists in the same location for more than 24 hours, leaves bruising when it fades, is painful rather than itchy, or does not respond to antihistamines warrants dermatologic evaluation to exclude urticaria mimics that require very different management.

Is Urticaria Dangerous?

Most urticaria, including the vast majority of chronic spontaneous urticaria cases, is not medically dangerous. It is not cancerous, does not cause permanent skin damage, and does not indicate serious underlying disease in the majority of affected patients.

However, urticaria can be associated with genuine medical risk in specific circumstances that require immediate recognition. Urticaria occurring as part of anaphylaxis, combined with systemic symptoms including throat tightening, difficulty breathing, drop in blood pressure, vomiting, or loss of consciousness, is a medical emergency requiring immediate epinephrine injection and emergency care. Angioedema involving the tongue, larynx, or throat can obstruct the airway and is similarly life-threatening. Urticarial vasculitis can indicate serious underlying systemic conditions including lupus erythematosus, hepatitis B or C infection, or malignancy. And new-onset urticaria can occasionally be the presenting sign of thyroid autoimmunity, which requires evaluation and management. These serious associations reinforce why professional evaluation of chronic or atypical urticaria is clinically important, not merely for comfort and quality of life, but to exclude conditions that carry real systemic significance.

Signs and Symptoms of Urticaria

Urticaria has characteristic features that make it recognizable once you know what to look for. Understanding those features, and knowing which accompanying symptoms signal a more serious reaction, helps patients respond appropriately and communicate clearly with their dermatologist about what they are experiencing.

The Wheal and Flare: The Defining Feature

The defining feature of urticaria is the wheal, a raised, pale or pink area of skin edema surrounded by an erythematous (red) flare. Wheals are superficial, forming in the upper dermis as histamine released from activated mast cells increases local vascular permeability and causes fluid to leak from blood vessels into surrounding skin tissue. They blanch completely when pressure is applied, which reflects their vascular origin. Individual wheals can be very small, a few millimeters in diameter, or very large, covering significant body surface area as adjacent wheals coalesce. They can be round, oval, or irregular. They can appear on any body surface including the face, trunk, extremities, hands, feet, and scalp. They do not form on mucous membranes.

Duration and Migration: The Most Important Diagnostic Clue

The most clinically important characteristic of urticaria, and the one that most reliably distinguishes it from mimicking conditions, is its transience. Individual wheals in true urticaria resolve within 24 hours, typically within 1 to 6 hours, without leaving any trace on the skin. No bruising, no hyperpigmentation, no scarring. As existing wheals resolve, new ones form elsewhere. This migrating pattern, in which the rash appears to move around the body while the patient continues to feel symptomatic, is the hallmark of urticaria and the feature that patients often describe as most puzzling and distressing. Any hive-like lesion that persists in the same location for longer than 24 hours, or that leaves a mark when it fades, should be evaluated by a dermatologist to exclude urticarial vasculitis or other mimicking conditions.

Itch

Pruritus is the primary and most disabling symptom of urticaria for most patients. The itch is driven by histamine’s direct activation of sensory nerve endings and can range from mild to severe enough to prevent sleep, concentration, and normal daily activities. Nocturnal itch is particularly disruptive and is one of the most consistent quality-of-life complaints in chronic urticaria. Patients with chronic spontaneous urticaria score significantly lower on quality-of-life measures than patients with many other dermatologic conditions, reflecting the cumulative impact of persistent, sleep-disrupting itch. The Urticaria Activity Score assessed over seven days, known as the UAS7, captures both wheal number and itch severity to provide a validated measure of disease activity that guides treatment decisions.

Angioedema

Angioedema occurs in approximately 40 percent of patients with chronic spontaneous urticaria and can occur alone or alongside hives. It presents as sudden, non-pitting swelling of the deeper tissues, most visibly affecting the lips, eyelids, hands, feet, and genitalia. Swelling can be asymmetric, dramatic, and distressing in appearance. Episodes typically develop over minutes to hours and resolve over 24 to 72 hours, slower than the resolution of superficial wheals. Gastrointestinal angioedema produces abdominal cramping, nausea, and diarrhea. Laryngeal angioedema produces hoarseness, throat tightness, stridor, and is a medical emergency requiring immediate epinephrine and emergency evaluation.

Presentation in Different Skin Tones

In lighter skin tones, urticarial wheals appear as pale, raised welts on a pink or red erythematous base, often visually dramatic and immediately recognizable. In medium and darker skin tones, the erythematous flare may be less visible, and the raised wheal may appear as skin-colored or subtly darker than the surrounding skin. The itch and the transient, migrating nature of the rash remain the same across skin tones and are critical diagnostic features when visual erythema is less prominent.

Symptoms That Require Immediate Medical Attention

While most urticaria is uncomfortable but not medically dangerous, certain accompanying symptoms indicate a potentially life-threatening reaction requiring emergency care. Call emergency services immediately or go to the nearest emergency room if you experience hives combined with any of the following:

•         Throat tightening, hoarseness, or stridor (high-pitched breathing sound)
•         Difficulty breathing or shortness of breath
•         Swelling of the tongue or throat
•         Drop in blood pressure, dizziness, or loss of consciousness
•         Rapid or irregular heartbeat
•         Nausea, vomiting, or severe abdominal pain accompanying hives
•         A sense of impending doom

Patients with a history of severe allergic reactions or angioedema involving the airway should carry a prescribed epinephrine auto-injector and have a written anaphylaxis action plan. Your dermatologist will coordinate this aspect of your care with your allergist or primary care physician as appropriate.

Symptoms That Warrant a Dermatology Appointment

See a dermatologist for evaluation of urticaria if you experience:

•         Hives occurring on most days for six weeks or longer
•         Hives that have not responded to over-the-counter antihistamines taken consistently
•         Recurring episodes without a clear identifiable trigger
•         Angioedema accompanying your hives
•         Hive-like lesions that persist in the same spot for longer than 24 hours
•         Hives associated with pain or burning rather than itch
•         Hives that leave a bruise or discoloration when they fade
•         Significant sleep disruption or quality-of-life impairment from hive episodes
•         Hives associated with systemic symptoms such as fever, joint pain, or fatigue

Risk Factors and Triggers for Urticaria

Urticaria develops when mast cells in the skin are activated beyond a threshold, releasing enough histamine to produce visible wheals. In acute urticaria, a specific trigger usually initiates this activation. In chronic spontaneous urticaria, the threshold is chronically lowered by autoimmune mechanisms that keep mast cells in a state of heightened reactivity. Understanding both the constitutional risk factors that raise susceptibility and the common triggers that initiate individual episodes helps patients manage their condition and informs the diagnostic evaluation.

Age and Sex

Acute urticaria affects people across all age groups, with peak incidence in children and young adults. Chronic spontaneous urticaria has its highest incidence between the ages of 20 and 40 and affects women approximately twice as frequently as men. The female predominance parallels the female predominance of autoimmune conditions generally and reflects the hormonal and immune regulatory differences that influence mast cell reactivity and autoantibody production.

Atopic Background

Individuals with a personal or family history of atopic dermatitis, allergic rhinitis, or asthma have elevated IgE levels and increased mast cell sensitization, raising their baseline susceptibility to urticaria, particularly acute IgE-mediated forms triggered by specific allergens. The atopic background does not directly cause chronic spontaneous urticaria, which has a distinct autoimmune mechanism, but it may lower the overall threshold for mast cell activation.

Autoimmune and Thyroid Disease

Autoimmune thyroid disease, including Hashimoto thyroiditis and Graves disease, is significantly more prevalent in patients with chronic spontaneous urticaria than in the general population. Thyroid autoantibodies, particularly anti-thyroid peroxidase antibodies, have been found in 25 to 30 percent of chronic spontaneous urticaria patients in multiple studies. While treating the thyroid disease does not reliably resolve the urticaria in all cases, the association is strong enough to warrant thyroid screening in patients with chronic urticaria. Other autoimmune conditions including lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, and inflammatory bowel disease are also associated with elevated urticaria prevalence.

Common Triggers for Acute Urticaria

Food Allergens: Foods are among the most commonly implicated triggers in acute urticaria. The most prevalent food allergens include shellfish, peanuts, tree nuts, fish, eggs, milk, wheat, and soy. In children, milk, eggs, and wheat are particularly common triggers. IgE-mediated food allergy produces urticaria typically within 15 to 30 minutes of ingestion, which helps establish the temporal relationship. Not all food-triggered urticaria is IgE-mediated; some foods trigger mast cell degranulation directly (pseudoallergens) without prior sensitization.

Medications: Medications are a major cause of both acute and chronic urticaria. NSAIDs including aspirin and ibuprofen are the most common drug triggers and act through cyclooxygenase inhibition rather than IgE-mediated mechanisms, meaning skin-prick testing will not predict these reactions. Antibiotics, particularly penicillins and cephalosporins, trigger IgE-mediated urticaria in sensitized individuals. ACE inhibitors cause bradykinin-mediated angioedema rather than histaminergic urticaria and do not respond to antihistamines. Opioids cause direct mast cell degranulation. Patients should bring a complete medication list to their dermatology evaluation and report any temporal associations between medication use and urticaria onset.

Infections: Infections, particularly viral upper respiratory tract infections, are the most common identifiable trigger of acute urticaria in children. Bacterial infections including Helicobacter pylori, dental abscesses, sinusitis, and urinary tract infections have been associated with chronic urticaria flares in some patients. Parasitic infections can trigger urticaria through eosinophil-mast cell interactions. Identification and treatment of active infections is a clinically appropriate step in the evaluation of new-onset or worsening chronic urticaria.

Insect Stings and Bites: Hymenoptera stings (bees, wasps, hornets, yellow jackets, fire ants) can trigger IgE-mediated urticaria and anaphylaxis in sensitized individuals. Patients who develop systemic urticaria following insect stings should undergo allergy evaluation for venom hypersensitivity and consideration of venom immunotherapy.

Triggers That Worsen Chronic Spontaneous Urticaria

Even in patients whose chronic spontaneous urticaria has an autoimmune basis that does not resolve with trigger removal, certain factors consistently exacerbate symptoms by lowering the mast cell activation threshold or amplifying the inflammatory response. The most common exacerbating factors include:

•         NSAIDs and aspirin: Worsen existing chronic spontaneous urticaria in approximately 30 percent of patients through prostaglandin pathway effects on mast cell activation. This is an intolerance reaction, not a true allergy, and should be reported to the dermatologist.
•         Psychological stress: Activates the hypothalamic-pituitary-adrenal axis and releases neuropeptides that lower the mast cell activation threshold. Most patients with chronic spontaneous urticaria identify stress as a consistent flare trigger.
•         Alcohol: Acts as a direct mast cell activator and vasodilator, exacerbating urticaria symptoms in many patients.
•         Physical factors: Heat, exercise, friction, and pressure can aggravate chronic spontaneous urticaria and overlap with inducible urticaria subtypes.
•         Hormonal changes: Menstrual cycle fluctuations, pregnancy, and oral contraceptive changes influence mast cell reactivity and can alter urticaria frequency and severity.

Can You Prevent Urticaria?

Complete prevention of urticaria is not achievable in most chronic cases because the underlying autoimmune mechanism operates independently of specific external triggers. However, several evidence-informed strategies meaningfully reduce episode frequency and severity.

Identify and Avoid Your Personal Triggers

Keeping a detailed symptom diary that records hive episodes alongside meals, medications, activities, environmental exposures, and stress levels over several weeks helps identify patterns that point toward specific triggers. Even in chronic spontaneous urticaria where no single causal trigger exists, identifying consistent exacerbating factors such as NSAID use, alcohol, or specific food additives enables targeted avoidance that reduces flare frequency.

Avoid Known NSAID and Aspirin Use When Possible

For the estimated 30 percent of chronic spontaneous urticaria patients who experience reliable worsening with NSAIDs, consistent avoidance of these medications and use of acetaminophen as an alternative analgesic substantially reduces flare burden. This single intervention produces meaningful improvement in a significant proportion of patients.

Maintain Continuous Antihistamine Therapy

Continuous daily second-generation H1 antihistamine therapy, taken on a scheduled basis rather than only during active episodes, maintains ongoing suppression of mast cell histamine effects and prevents the cycle of reactivity that produces frequent breakthrough episodes. Reactive dosing after wheals appear is significantly less effective than consistent prophylactic dosing.

Manage Stress and Sleep

Stress management through regular exercise, adequate sleep, and mindfulness practices has documented benefit in reducing urticaria flare frequency. Adequate sleep is independently important because sleep deprivation lowers the mast cell activation threshold and worsens itch perception and intensity.

Diagnosis and Evaluation of Urticaria

Urticaria is primarily a clinical diagnosis confirmed through history and physical examination. Laboratory testing is targeted rather than comprehensive and is guided by the duration, pattern, and associated features of the patient’s urticaria. The diagnostic process serves three interconnected goals: confirming that the skin condition is urticaria and not a mimicking condition, classifying the type of urticaria to guide treatment, and identifying any underlying or contributing causes that can be addressed to improve control.

Clinical History

A detailed, systematic history is the most valuable diagnostic tool in urticaria evaluation. Your dermatologist will document the timeline of your hives, how long individual wheals last, their size, distribution, and frequency, and whether they are accompanied by angioedema. Temporal associations with food, medications, infections, exercise, heat, cold, pressure, stress, or menstrual cycle changes are carefully explored. Your complete medication list is reviewed with particular attention to NSAIDs, ACE inhibitors, and antibiotics. Dietary history, supplement use, and occupational and recreational exposures are documented. Prior episodes, previous treatments and their outcomes, and personal and family histories of atopy, autoimmune conditions, and thyroid disease all contribute to the diagnostic assessment.

Physical Examination

If hives are present at the time of your appointment, your dermatologist examines the wheals directly, assessing their morphology, distribution, size, and whether they blanch completely with pressure. They check for dermographism by stroking the forearm skin firmly and observing for wheal formation, which is positive in symptomatic dermographism and present to some degree in many urticaria patients. Angioedema sites are documented. Any features suggesting a mimicking condition, such as persistent lesions, pigmented residue, purpura, or target morphology, are noted and guide additional evaluation.

Urticaria Activity Score (UAS7)

The Urticaria Activity Score over seven days is a validated patient-reported outcome tool used in chronic urticaria management. Patients record wheal count and itch intensity each morning and evening for seven consecutive days, producing a total score from 0 to 42 that quantifies disease activity. The UAS7 guides treatment decisions, determines when step-up therapy is indicated, tracks response to treatment over time, and establishes eligibility for advanced therapies including omalizumab. Your dermatologist will explain how to complete and track your UAS7 score.

Laboratory Workup

For acute urticaria with a probable identifiable trigger, extensive laboratory workup is typically not required. For chronic urticaria lasting more than six weeks, a targeted baseline evaluation is clinically appropriate. Standard initial testing includes a complete blood count with differential to screen for eosinophilia or other hematologic abnormalities, a comprehensive metabolic panel, thyroid-stimulating hormone and thyroid autoantibody levels, and a C-reactive protein or erythrocyte sedimentation rate to screen for systemic inflammation. Total serum IgE may be obtained. These investigations are not expected to identify a specific cause in most cases but do screen for the treatable underlying conditions, particularly thyroid autoimmunity, that are meaningfully associated with chronic urticaria.

Allergen Testing

Skin-prick testing or serum-specific IgE testing for suspected food or environmental allergens is appropriate in acute urticaria with a suspected IgE-mediated trigger, particularly if the history suggests a consistent temporal relationship with a specific food or insect sting. In chronic spontaneous urticaria, allergy testing is not routinely indicated because a specific IgE-mediated allergen is rarely the driving mechanism. Ordering broad allergy panels without a specific clinical indication produces misleading results, generates unnecessary dietary restrictions, and does not improve urticaria control.

Provocation Testing for Chronic Inducible Urticaria

When a chronic inducible urticaria subtype is suspected, standardized provocation tests reproduce the suspected trigger under controlled conditions to confirm the diagnosis and establish the reaction threshold. The ice cube test applies a standardized cold stimulus to the forearm for a defined time period to diagnose cold urticaria and determine the cold threshold temperature. Dermographometry measures the pressure required to produce dermographism. An exercise challenge or hot water immersion can confirm cholinergic urticaria. Photoprovocation with a solar simulator confirms solar urticaria. These tests guide both the diagnosis and the practical counseling about safe threshold levels for daily activities.

Skin Biopsy

Skin biopsy is not required for typical urticaria. It is indicated when urticarial vasculitis cannot be excluded, when lesions persist beyond 24 hours in the same location, when lesions are painful or burning rather than pruritic, when pressure produces no blanching, or when systemic symptoms suggest an underlying condition requiring tissue diagnosis. The biopsy is taken from an active lesion and processed with both routine histopathology and direct immunofluorescence when vasculitis or an autoimmune blistering disease is suspected. Urticarial vasculitis demonstrates fibrinoid necrosis of vessel walls and neutrophilic infiltration with leukocytoclasis on histology, findings that are entirely distinct from benign urticaria.

When Should You Get Urticaria Evaluated?

You should see a dermatologist if you notice:

•         Hives persisting on most days for six weeks or longer
•         Recurrent episodes without a clear identifiable trigger
•         Hives that have not responded to consistent over-the-counter antihistamine use
•         Angioedema occurring with or without hives
•         Hive-like lesions that stay in the same location for more than 24 hours
•         Lesions that are painful or burning rather than itchy, or that leave a bruise when they fade
•         Hives associated with fever, joint pain, fatigue, or other systemic symptoms
•         Sleep disruption or significant quality-of-life impairment from urticaria symptoms
•         Any urticaria episode accompanied by throat tightening or difficulty breathing

Urticaria Treatment Options

Urticaria treatment follows a well-established, evidence-based stepwise approach endorsed by the European Academy of Allergy and Clinical Immunology, the American Academy of Allergy, Asthma and Immunology, and the American Academy of Dermatology. The treatment ladder moves progressively through therapies of increasing potency and complexity based on the patient’s response at each step. The goal is complete symptom control, defined as a UAS7 score of zero and freedom from angioedema, using the simplest effective intervention. The specific steps and the speed with which a patient advances through them are guided by disease severity and treatment response.

Step One: Second-Generation H1 Antihistamines at Standard Dose

Second-generation, non-sedating H1 antihistamines are the universal first-line treatment for all forms of urticaria. They competitively block histamine H1 receptors on blood vessel walls and sensory nerve endings, reducing vasodilation, vascular permeability, and pruritus. The available agents include cetirizine, loratadine, fexofenadine, desloratadine, bilastine, and levocetirizine. They are taken once daily at standard labeled doses and produce meaningful improvement in most patients with mild to moderate urticaria. Second-generation antihistamines are far preferred over first-generation agents such as diphenhydramine for daily urticaria management because they do not produce clinically significant sedation, cognitive impairment, or the anticholinergic side effects associated with older antihistamines. First-generation agents may be used sparingly at night when sedation is accepted and nocturnal itch control is the priority, but they should not form the backbone of daily urticaria management.

Step Two: Second-Generation H1 Antihistamines at Updosed Doses

For patients with chronic urticaria that is not adequately controlled at standard antihistamine doses, increasing the dose of a second-generation antihistamine up to four times the standard labeled dose is an evidence-supported and guideline-recommended next step before advancing to biologic therapy. Multiple clinical trials demonstrate that up-dosing produces additional benefit in a meaningful proportion of patients. The higher doses remain well tolerated with second-generation agents, which maintain their favorable sedation and safety profile at doses up to four times standard. If one antihistamine fails to provide adequate control at up-dosed levels, switching to a different second-generation antihistamine agent is an appropriate additional step, as individual patients sometimes respond preferentially to one agent over another due to pharmacokinetic differences.

Adjunctive H2 Antihistamines and Leukotriene Receptor Antagonists

H2 antihistamines such as famotidine, which block histamine H2 receptors on blood vessels and in the gastrointestinal tract, can provide modest additional symptom control when added to H1 antihistamine therapy in some patients. Leukotriene receptor antagonists such as montelukast may provide supplemental benefit, particularly in patients with NSAID-exacerbated urticaria or those with concurrent allergic rhinitis, by blocking leukotriene-mediated mast cell inflammatory signaling. These agents are adjuncts rather than primary therapies and are most valuable in patients who need additional control beyond what antihistamine monotherapy achieves.

Step Three: Omalizumab (Xolair)

Omalizumab is an anti-IgE monoclonal antibody that binds free circulating IgE and prevents it from binding to its receptor on mast cells, dramatically reducing the mast cells’ capacity for IgE-triggered activation and degranulation. It is FDA-approved for chronic spontaneous urticaria in patients 12 years and older who remain symptomatic despite H1 antihistamine therapy and represents the most significant advance in urticaria treatment of the past two decades. Administered as a subcutaneous injection of 300 mg every four weeks in a clinical setting, omalizumab produces complete symptom control in approximately 50 to 60 percent of antihistamine-refractory chronic urticaria patients in clinical trials and meaningful improvement in an additional 20 to 30 percent. Onset of benefit can be rapid, within days in some patients, or may take 12 to 16 weeks to reach maximum effect. It is generally very well tolerated. Injection site reactions are the most common side effect. Anaphylaxis is rare but possible, which is why injections are administered in a healthcare setting with observation.

Omalizumab is used for chronic spontaneous urticaria that does not respond to antihistamines at up-dosed levels. It is not a permanent cure; most patients experience gradual return of symptoms after discontinuation, and many patients benefit from ongoing therapy for one to several years while the condition follows its natural course toward eventual spontaneous remission.

Step Four: Cyclosporine

For patients with severe chronic spontaneous urticaria who do not respond adequately to omalizumab, cyclosporine, a calcineurin inhibitor that suppresses T-cell activation and mast cell IgG autoantibody-driven degranulation, provides meaningful disease control in many cases. It is used off-label for urticaria and requires monitoring for blood pressure elevation, renal function changes, and drug interactions. Treatment courses are typically 3 to 6 months in duration, and response rates in antihistamine-refractory patients are documented in multiple clinical studies. Cyclosporine is reserved for the most treatment-resistant cases due to its side effect profile and monitoring requirements.

Short Courses of Systemic Corticosteroids

Oral corticosteroids such as prednisone provide rapid, highly effective suppression of urticaria and angioedema in severe acute episodes or during particularly intense flares. They are appropriate for short-term rescue use, typically 3 to 7 days, to bring a severe acute episode under control while underlying management is optimized. They are not appropriate for chronic urticaria management because the condition’s natural course is long, the risks of prolonged corticosteroid use are substantial, and superior targeted therapies including omalizumab are available. The international guidelines for chronic urticaria management explicitly discourage the use of systemic corticosteroids beyond brief rescue courses.

Managing Chronic Inducible Urticaria

Chronic inducible urticaria subtypes share the same antihistamine-first approach used for chronic spontaneous urticaria but additionally require specific trigger management strategies unique to each subtype. Cold urticaria requires avoidance of cold exposure and carries an anaphylaxis risk with cold water immersion that mandates an epinephrine auto-injector and restrictions on unsupervised swimming. Cholinergic urticaria requires heat and exercise threshold management and may respond well to frequent exercise desensitization protocols under medical guidance. Solar urticaria requires broad-spectrum photoprotection and may respond to phototherapy desensitization in specialized settings. Delayed pressure urticaria is among the most resistant to antihistamine therapy and often requires alternative anti-inflammatory agents.

Emerging Therapies

The biologic landscape for urticaria is rapidly evolving. Ligelizumab, a higher-affinity anti-IgE monoclonal antibody than omalizumab, is in late-stage clinical development. Remibrutinib and other Bruton tyrosine kinase inhibitors target an upstream signaling pathway in mast cell activation and are demonstrating significant efficacy in clinical trials for both antihistamine-refractory and omalizumab-refractory chronic spontaneous urticaria. Dupilumab has shown benefit in a subset of chronic urticaria patients, particularly those with an atopic background and Th2-skewed inflammation. These emerging agents represent the next generation of precision-targeted urticaria therapy and offer hope for patients with the most treatment-resistant disease.

Why Choose Connolly Dermatology for Urticaria Treatment

Care Guided by Experience and Clinical Judgment

Urticaria is extremely common but can be extraordinarily difficult to manage without the right expertise. Patients frequently cycle through reactive antihistamine use, imprecise trigger avoidance, and poorly guided steroid courses before receiving the systematic, guideline-adherent evaluation that produces real long-term control. Connolly Dermatology provides comprehensive, physician-led urticaria care that moves through the evidence-based treatment ladder deliberately, identifies the correct urticaria type and subtype, excludes mimicking conditions, and accesses the full spectrum of available therapies including omalizumab biologic treatment for antihistamine-refractory disease.

Board-Certified Dermatologists

Our dermatologists are experienced in managing the complete spectrum of urticaria presentations, from straightforward acute allergic reactions through complex chronic spontaneous urticaria with concurrent angioedema, and in distinguishing urticaria from the several conditions, including urticarial vasculitis and bullous pemphigoid, that require entirely different treatment approaches. Every recommendation reflects current international guideline standards.

Accurate Diagnosis Before Treatment

The most common reason urticaria is poorly controlled is inadequate diagnosis. Treating urticarial vasculitis as standard urticaria, or managing chronic inducible urticaria as chronic spontaneous urticaria, produces poor outcomes because the wrong mechanism is targeted. We perform the clinical examination, provocation testing, and biopsy when indicated to confirm exactly what type of urticaria you have before designing your management plan.

Access to Omalizumab and Biologic Therapy

For patients with antihistamine-refractory chronic spontaneous urticaria, omalizumab represents a transformative treatment advance. We administer omalizumab for eligible patients and monitor treatment response systematically using validated tools including the UAS7. Patients who have been living with poorly controlled chronic urticaria for months or years often experience dramatic, rapid improvement with biologic therapy initiated through a proper evaluation and treatment pathway.

Stepwise, Guideline-Adherent Management

We follow the international guideline-endorsed treatment ladder for urticaria, advancing through evidence-supported steps based on your specific response rather than defaulting to corticosteroids or undertreating with single-dose antihistamines. The goal is complete symptom control at the simplest effective treatment level, and we track your progress using validated severity scoring to make treatment decisions transparent and evidence-grounded.

Honest Communication About Outcomes

Chronic urticaria is a condition with a variable natural course. We tell every patient that clearly. Approximately 50 percent of patients with chronic spontaneous urticaria achieve spontaneous remission within one year, and the majority are in remission within five years, though some patients have a more prolonged course. Effective management during the active disease period dramatically reduces the daily impact of the condition while allowing it to follow its natural remission trajectory. We set realistic expectations from the first visit.

Patient Education and Support

Understanding why your hives move and change, how the treatment ladder works, when to use rescue therapy versus daily prevention, and how to track your own disease activity with the UAS7 makes you a far more informed and effective participant in your own care. We make this education a core component of every urticaria consultation.

Comfortable, Compassionate Care

Living with chronic hives, particularly when they disrupt sleep nightly and appear unpredictably during work and social interactions, is genuinely exhausting and demoralizing. Our team understands that and approaches every urticaria consultation with the seriousness and compassion the condition deserves.

What To Expect During Treatment

Guiding You Through Evaluation and the Next Steps

For patients who have been dealing with recurrent or chronic hives without a clear explanation or effective treatment plan, a dermatology evaluation often represents the first structured approach to a condition they have been managing reactively for months or years. At Connolly Dermatology, we guide you through every step of the evaluation and treatment process so you understand what to expect and feel confident in the path forward.

Before Your Appointment

Preparing thoroughly before your visit significantly improves the quality of your evaluation. For the two weeks before your appointment, keep a daily diary of your hive episodes, recording when they occur, where on your body, how long individual wheals last, how intense the itch is on a scale of zero to ten, whether angioedema is present, and anything you consumed, did, or were exposed to in the hours before each episode. Document every medication and supplement you take, including all over-the-counter antihistamines and pain relievers. Note any associations you have already observed between your hives and specific foods, activities, temperatures, stress, or other exposures. Bring your complete medical history including any known allergies, autoimmune conditions, and thyroid history. This preparation gives your dermatologist a rich clinical picture before the examination begins.

During the Evaluation

Your dermatologist reviews your history in detail and then performs a focused physical examination. If hives are present, they are examined directly. Dermographism is tested. The pattern and duration of your lesions are assessed for features that distinguish typical urticaria from mimicking conditions. Provocation testing for an inducible subtype is performed when the history suggests a specific physical trigger.

Your dermatologist explains the type of urticaria most consistent with your presentation, shares their diagnostic assessment, and discusses the treatment plan before anything is prescribed. For most patients with chronic spontaneous urticaria, the initial plan begins with second-generation H1 antihistamine therapy at the appropriate dose. Laboratory testing is ordered when indicated. The UAS7 tracking tool is explained and a follow-up timeline is established to assess treatment response.

Patients whose history suggests a possible trigger not yet identified are guided through a structured diary-based investigation. Patients with atypical features are counseled about the possibility of a biopsy before initiating treatment, so there is no delay in obtaining tissue from an active lesion if needed.

After Your First Visit

Most patients with mild to moderate urticaria experience meaningful improvement within 1 to 2 weeks of starting daily second-generation antihistamine therapy at the appropriate dose. Patients advancing to up-dosed antihistamine levels may see further improvement over the subsequent weeks. Response is tracked with the UAS7 and assessed at follow-up appointments scheduled 4 to 8 weeks after initiation.

For patients who do not achieve adequate control on antihistamine therapy after a defined trial period, advancement to omalizumab is discussed and the process of initiating biologic therapy is explained. Monthly omalizumab injections are administered in our office. Many patients notice rapid improvement within the first injection cycle, while others require 3 to 4 monthly injections before reaching their maximum benefit. Response is reassessed at each visit using UAS7 tracking.

Throughout your care, your dermatologist remains accessible for questions between appointments, adjusts your treatment plan based on documented response, and ensures you have a rescue plan for severe flares or angioedema episodes. For patients with a history of angioedema or anaphylaxis, epinephrine auto-injector prescription and an action plan are integrated into your overall care.

Get Clear Answers from Connolly Dermatology

Make Informed Decisions About Your Skin Health

Urticaria is a common, often chronic, and genuinely disruptive condition driven by mast cell activation that produces the characteristic itchy, migrating wheals that define the condition. In its acute form it is usually self-limiting. In its chronic form it can persist for years, disrupt sleep nightly, and significantly impair quality of life. It encompasses distinct subtypes, including chronic spontaneous urticaria with its autoimmune mechanisms and the inducible subtypes triggered by specific physical stimuli, that require different diagnostic approaches and different management strategies.

Effective management requires accurate diagnosis to confirm the correct urticaria type and exclude mimicking conditions such as urticarial vasculitis and bullous pemphigoid. It requires a systematic, guideline-adherent treatment approach that progresses from second-generation antihistamines through up-dosing to omalizumab biologic therapy for antihistamine-refractory disease. And it requires patient education that empowers you to track your own disease activity, identify your exacerbating factors, and use your treatment plan as the preventive daily strategy it is meant to be.

If hives are recurring frequently, disrupting your sleep, or affecting your quality of life, a professional evaluation provides the structured, evidence-based approach that produces real long-term control. At Connolly Dermatology, our board-certified dermatologists offer expert assessment, accurate diagnosis, and the full spectrum of urticaria treatments from antihistamine optimization through biologic therapy.

Schedule a visit with a dermatologist to get clear, informed guidance about your skin.